评价莫西沙星及利福布丁方案对初次复治涂阳肺结核超短程治疗效果及安全性

Evaluation of Super Short Treatment Effect and Safety of Moxifloxacin and Rifabutin Scheme for Initial Smear Positive Pulmonary Tuberculosis

目的探讨对初次复治涂阳肺结核患者采用莫西沙星及利福布丁方案开展超短程治疗的临床疗效及安全性。方法将我院2014年8月～2015年8月收治的初次复治涂阳肺结核患者68例选为研究对象,探讨其临床疗效及安全性。结果治疗后64.7%患者痰菌转阴,26.5%患者无痰,8.8%患者痰菌及痰结核菌培养阳性;行胸部CT检查显示91.2%患者病灶明显吸收,8.8%患者吸收不明显。结论莫西沙星及利福布丁方案对初次复治涂阳肺结核超短程治疗效果较好。

Objective To explore the clinical efficacy and safety of short-term treatment of the initial retreatment smear positive pulmonary tuberculosis patients used moxifloxacin and rifabutin scheme.Methods In our hospital, during August 2014~August 2015, 68 cases with smear positive pulmonary tuberculosis were chosen as the research object, to explore the clinical efficacy and safety.Results After treatment, 64.7% patients had the sputum negative conversion, 26.5% without phlegm, 8.8%of sputum and sputum culture positive, chest CT scan showed obvious 91.2% lesions absorption, 8.8% absorption was not obvious.Conclusion The effect of moxilfoxacin and rifabutin scheme for initial smear positive pulmonary tuberculosis super short treatment is good.